Literature DB >> 10390068

Fine needle aspiration biopsy of the spleen in pyrexia of unknown origin.

A Rajwanshi1, D Gupta, S Kapoor, R Kochhar, S Gupta, S Varma, S Gupta.   

Abstract

To evaluate the diagnostic utility, value and potential risk of fine needle aspiration biopsy of spleen (sFNAB) in patients with splenomegaly in pyrexia of unknown origin (PUO), a retrospective analysis of medical records and cytological material of 31 patients on whom FNAB was performed between April 1994 and October 1997 was done. The patients were HIV- and presented with PUO. All other relevant investigations were negative. The spleen was either palpable or detected to have space-occupying lesions on ultrasonography (USG). The splenic aspirates showed tuberculosis in 11 patients (35.4%) and inconclusive or reactive changes in nine patients (25.8%). One case out of this group proved to be Kaposi's sarcoma on autopsy. The other diseases encountered were leishmaniasis (n = 3), non-Hodgkin's lymphoma (n = 4), fungal infections (n = 2), Hodgkin's lymphoma (n = 1). The patients who were diagnosed as having tuberculosis had epithelioid cells, giant cells, necrosis and inflammatory cells in various combinations. AFB positivity was 63.6%. The other cases which showed granulomas but no AFB were diagnosed on empirical grounds and all responded to the anti-tuberculosis therapy. No complications were encountered with the procedure. Therefore the authors conclude that sFNAB is rewarding in patients where all other non-invasive modalities of diagnosis have failed.

Entities:  

Mesh:

Year:  1999        PMID: 10390068     DOI: 10.1046/j.1365-2303.1999.00170.x

Source DB:  PubMed          Journal:  Cytopathology        ISSN: 0956-5507            Impact factor:   2.073


  1 in total

1.  Primary Splenic Angiosarcoma with Liver Metastasis: A Rare Neoplasm Diagnosed on Fine-needle Aspiration Cytology and Cell Block Immunocytochemistry.

Authors:  Saniya Sharma; Priya Singh; Pankaj Gupta; Anupam Lal; Radhika Srinivasan
Journal:  J Cytol       Date:  2018 Apr-Jun       Impact factor: 1.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.